Loading clinical trials...
Loading clinical trials...
Stimulating Adipose Tissue Fatty Acid Disposal With Low-dose, Postprandial, Intermittent Niacin for the Treatment of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD).
Conditions
Interventions
Niacin (250mg)
Placebo Oral Tablet
Locations
1
Canada
Centre de recherche du CHUS
Sherbrooke, Quebec, Canada
Start Date
April 1, 2026
Primary Completion Date
March 1, 2030
Completion Date
July 1, 2030
Last Updated
February 10, 2026
NCT05395481
NCT07480811
NCT07133854
NCT06647095
NCT04282005
Lead Sponsor
Université de Sherbrooke
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions